The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

International Agency for Research on Cancer, World Health Organization, 2014, GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012

National Comprehensive Cancer Network. Non-small cell lung cancer. 2015. www.nccnorg/professionals/physician_gls/PDF/nsclpdf Accessed Apr 13, 2015.

Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. The Cochrane database of systematic reviews. 2010. https://www.nccnorg/professionals/physician_gls/pdf/nsclpdf. CD007309.

Quintás-Cardama, 2011, Treatment of non-small-cell lung cancer with erlotinib or gefitinib, New England Journal of Medicine, 364, 947, 10.1056/NEJMct0807960

Ichinose, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, New England Journal of Medicine, 361, 947, 10.1056/NEJMoa0810699

Kinoshita, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, New England Journal of Medicine, 362, 2380, 10.1056/NEJMoa0909530

Hirashima, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The lancet oncology, 11, 121, 10.1016/S1470-2045(09)70364-X

Suh, 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, Journal of Clinical Oncology, 30, 1122, 10.1200/JCO.2011.36.8456

Boyer, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, Journal of Clinical Oncology, 31, 3327, 10.1200/JCO.2012.44.2806

Sanchez, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The lancet oncology, 13, 239, 10.1016/S1470-2045(11)70393-X

Ren, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, The lancet oncology, 12, 735, 10.1016/S1470-2045(11)70184-X

Zhou, Wu, Chen, Feng, Liu, Wang, Zhang, Wang, Zhou, Ren. 2011. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). Paper presented at: ASCO Annual Meeting Proceedings 2011. ASCO Annual Meeting Proceedings; p. 7520.

Porta, 2011, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, Journal of clinical oncology, 29, abs7503, 10.1200/jco.2011.29.15_suppl.7503

Pazdur, 2005, FDA drug approval summary: erlotinib (Tarceva®) tablets, The oncologist, 10, 461, 10.1634/theoncologist.10-7-461

Pazdur, 2003, FDA drug approval summary: gefitinib (ZD1839)(Iressa®) tablets, The oncologist, 8, 303, 10.1634/theoncologist.8-4-303

Gefitinib approved for use in South Korea. Inpharma Wkly. 2003; 1398–22.

Roche. Tarceva approved for lung cancer in Japan 2007. http://www.pharmatimescom/news/japan_approves_ roches_tarceva_for_non-small_cell_lung_cancer_991183 Accessed Nov 23, 2015.

China Food Drug Administration. CFDA drug approval for gefitinib. 2014. http://www.astrazenecacomcn/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3D261312979027801pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285710811655&ssbinary=true Accessed Nov 24, 2015.

U.S. Food and Drug Administration. FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm Accessed Nov 24, 2015.

Nordquist, 2011, 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer, Journal of Clinical Oncology, 29, 3825, 10.1200/JCO.2010.34.2774

Smit, 2010, Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop, Journal of Thoracic Oncology, 5, 1706, 10.1097/JTO.0b013e3181f1c8de

Yano, 2006, A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma, Japanese journal of clinical oncology, 36, 69, 10.1093/jjco/hyi228

Tsai, 2005, Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer, Clinical cancer research, 11, 3750, 10.1158/1078-0432.CCR-04-1981

Daneshmand, 2005, Erlotinib in lung cancer—molecular and clinical predictors of outcome, New England Journal of Medicine, 353, 133, 10.1056/NEJMoa050736

Domenichini, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, Journal of the National Cancer Institute, 97, 643, 10.1093/jnci/dji112

Yatabe, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, Journal of Clinical Oncology, 23, 2513, 10.1200/JCO.2005.00.992

Mezzetti, 2005, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment, Journal of Clinical Oncology, 23, 857, 10.1200/JCO.2005.08.043

Chung, 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, Journal of clinical oncology, 23, 2493, 10.1200/JCO.2005.01.388

Shimizu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, Journal of the National Cancer Institute, 97, 339, 10.1093/jnci/dji055

Johnson, 2005, Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology, Journal of Clinical Oncology, 23, 3227, 10.1200/JCO.2005.09.985

Yang, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), Journal of Thoracic Oncology, 9, 154, 10.1097/JTO.0000000000000033

Mitsudomi, 2004, Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications, Cancer research, 64, 8919, 10.1158/0008-5472.CAN-04-2818

Haber, 2007, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, 7, 169, 10.1038/nrc2088

Blowers, 2013, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Annals of Oncology, mdt205

Prochorec-Sobieszek, 2013, EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence, International journal of clinical and experimental pathology, 6, 2800

McCormack, 2015, EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII), American journal of cancer research, 5, 2892

Wang, 2014, EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis, International journal of clinical and experimental medicine, 7, 1967

Wu, 2012, EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: A meta-analysis, Environmental and molecular mutagenesis, 53, 78, 10.1002/em.20680

Mitsudomi, 2012, Impact of age on epidermal growth factor receptor mutation in lung cancer, Lung Cancer, 78, 207, 10.1016/j.lungcan.2012.09.006

Kris, 2011, Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas, Journal of Clinical Oncology, 29, 2066, 10.1200/JCO.2010.32.6181

Taron, 2012, Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma, European Respiratory Journal, 39, 366, 10.1183/09031936.00010111

Li, 2010, Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer, Acta Academiae Medicinae Sinicae, 32, 151

Cai, 2015, Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology-Mainland China Subset Analysis of the PIONEER study, PloS one, 10, e0143515, 10.1371/journal.pone.0143515

Somerfield, 2014, Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists/international society for the study of lung cancer/association of molecular pathologists guideline, Journal of Clinical Oncology. 2014:JCO, 2057

Finkelstein, 2012, Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung, Cancer, 118, 1032, 10.1002/cncr.26372

Shi, 2011, Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach, Journal of Thoracic Oncology, 6, 1663, 10.1097/JTO.0b013e318227816a

Liu, 2016, Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer, Oncotarget, 7, 29154, 10.18632/oncotarget.8684

Zhao, 2012, National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China, Lung Cancer, 77, 371, 10.1016/j.lungcan.2012.04.014

Shim, 2013, EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital, PloS one, 8, e56011, 10.1371/journal.pone.0056011

Haga, 2013, Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients, Journal of Thoracic Oncology, 8, 52, 10.1097/JTO.0b013e3182769aa8

Laird, 1986, Meta-analysis in clinical trials, Controlled clinical trials, 7, 177, 10.1016/0197-2456(86)90046-2